Challenges in the design of a Home Telemanagement Trial for patients with ulcerative colitis

Abstract

Background Nonadherence, inadequate monitoring, and side-effects result in suboptimal outcomes in ulcerative colitis (UC). We hypothesize that telemanagement for UC will improve symptoms, quality of life, adherence, and decrease costs. Purpose This article describes the challenges encountered in the design of the home telemanagement in patients with UC trial.

Methods In a randomized trial to assess the effectiveness of telemanagement for UC compared to best available care, 100 patients will be enrolled. Subjects in the intervention arm will complete self-testing with telemanagement weekly; best available care subjects will receive scheduled follow up, educational fact sheets, and written action plans. Telemanagement consists of a home-unit, decision support server, and web-based clinician portal. The home-unit includes a scale and laptop. Subjects will respond to questions about symptoms, side-effects, adherence, and knowledge weekly; subjects will receive action plans after self-testing. Outcome variables to be assessed every 4 months include: disease activity, using the Seo index; quality of life, using the Inflammatory Bowel Disease Questionnaire; adherence, using pharmacy refill data and the Morisky Medication Adherence Scale; utilization of healthcare resources, using urgent care visits and hospitalizations.

Results We encountered several challenges during design and implementation of our trial. First, we selected a randomized controlled trial design. We could have selected a quasiexperimental design to decrease the sample size needed and costs. Second, identification of a control group was challenging. Telemanagement patients received self-care plans and an educational curriculum. Since controls would not receive these interventions, we thought our results would be biased in favor of telemanagement. In addition, we wanted to evaluate the mode of delivery of these components of care. Therefore, we included written action plans and educational materials for patients in the control group (‘best available care’). Third, we could not blind subjects to group assignment. In an attempt to decrease bias, staff was masked to group assignment to decrease measurement bias. Fourth, we selected outcome measures that were not invasive to decrease risks to subjects and to enhance recruitment.

Limitations Our results may not be generalizable as our program is a tertiary center. Further, subjects are not blinded to the intervention potentially resulting in bias; we attempt to minimize this bias by having staff masked to treatment group at the time of assessment of outcome measures.

Conclusions To the best of our knowledge, our trial will be the first randomized controlled trial to evaluate telemedicine in subjects with gastrointestinal disease. We describe several issues encountered in design and implementation of our trial that will aid investigators when planning telemedicine trials in inflammatory bowel disease. Clinical Trials 2009; 6: 649–657. http://ctj.sagepub.com

Get full access to this article

View all access options for this article.

References

Kane S. , Huo D. , Aikens J. et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43.

Kane S. , Dang J. Medication taking behavior in a gastroenterology clinic: A disconnect between patient behavior and physician knowledge. Gastroenterology 2004; 126: A605.

Cross RK , Lapshin O. , Finkelstein J. Patient subjective assessment of drug side effects in inflammatory bowel disease . J Clin Gastroenterol 2008; 42: 244-51.

Cross RK , Wilson KT , Binion DG Polypharmacy and Crohn’s disease. Aliment Pharmacol Ther 2005; 21: 1211-16.

Wagner EH Chronic disease management: what will it take to improve care for chronic illness?. Eff Clin Pract 1998; 1: 2-4.

Finkelstein J. , Khare R. , Vora D. Home Automated Telemanagement (HAT) system to facilitate self care of patients with chronic diseases. JSCI 2003; 1: 78-82.

Finkelstein J. , Cabrera M. , Hripcsak G. Internet-based home asthma telemonitoring: can patients handle the technology?. Chest 2000; 117: 148-55.

Finkelstein J. , Khare R. , Vora D. , Arora M. Design and implementation of Home Automated Telemanagement in chronic obstructive pulmonary disease. In: Proceedings of the 16th IEEE Symposium on Computer-based Medical Systems, 26-27 June 2003, IEEE Computer Society Press, New York, Piscataway (NJ), p. 207.

Finkelstein J. , Cha E. Hypertension telemanagement in African Americans . Circ Cardiovasc Qual Outcomes 2009; 2: 272-8.

10.

Finkelstein J. , Khare R. , Ansell J. Feasibility and patients’ acceptance of Home Automated Telemanagement of oral anticoagulation therapy. AMIA Annu Symp Proc 2003230-34.

11.

Finkelstein J. , Lapshin O. , Castro H. et al. Home-based physical telerehabilitation in patients with multiple sclerosis: a pilot study. J Rehab Res Dev 2008; 45: 1361-74.

12.

Cross RK , Finkelstein J. Feasibility and acceptance of a home telemanagement system in patients with inflammatory bowel disease: a 6-month pilot study. Dig Dis Sci 2007; 52: 357-64.

13.

Cross RK , Arora M. , Finkelstein J. Acceptance of telemanagement is high in patients with inflammatory bowel disorder . J Clin Gastroenterol 2006; 40: 200-08.

14.

Seo M. , Okada M. , Yao T. et al. An index of disease activity in patients with ulcerative colitis . Am J Gastroenterol 1992; 87: 971-76.

15.

Seo M. , Okada M. , Yao T. et al. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts’ classification. Am J Gastroenterol 1995; 90: 1759-63.

16.

Guyatt G. , Mitchell A. , Irvine EJ et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-10.

17.

Hlavaty T. , Persoons P. , Vermeire S. et al. Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn’s disease. Inflamm Bowel Dis 2006; 12: 199-204.

18.

Irvine EJ , Feagan B. , Rochon J. et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-96.

19.

Powell-Tuck J. , Bown RL , Lennard-Jones JE A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833-37.

20.

Morisky DE , Green LW , Levine DM Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74.

21.

Rutgeerts P. , Feagan BG , Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 402-13.

22.

Lichtenstein GR , Yan S. , Bala M. et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease . Gastroenterology 2005; 128: 862-69.

23.

Radloff L. The CES-D scale: a self report depression scale for research in the general population. Appl PsycholI Measurement 1977 ; 1: 385-401.

24.

Eaden JA , Abrams K. , Mayberry JF The Crohn’s and Colitis Knowledge Score: a test for measuring patient knowledge in inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3560-66.

25.

Sewitch MJ , Abrahamowicz M. , Dobkin PL et al. Measuring differences between patients’ and physicians’ health perceptions: the patient-physician discordance scale. J Behav Med 2003; 26: 245-64.

26.

Miller RG Jr. Simultaneous Statistical Inference (2nd edn). Springer-Verlag, New York, NY, 1980.

27.

Higgins PD , Schwartz M. , Mapili J. et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005 ; 54: 782-88.

28.

Higgins PD , Schwartz M. , Mapili J. et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol 2005; 100: 355-61.